Antibody Information
General Information of This Antibody
| Antibody ID | ANI0FENLA |
|||||
|---|---|---|---|---|---|---|
| Antibody Name | Anti-LSR mAb |
|||||
| Synonyms |
Anti-LSR mAb (#16-6)
Click to Show/Hide
|
|||||
| Antibody Type | Monoclonal antibody (mAb) |
|||||
| Antibody Subtype | Humanized IgG2-kappa |
|||||
| Antigen Name | Lipolysis-stimulated lipoprotein receptor (LSR) |
Antigen Info | ||||
The Activity Data of This Antibody
| Antibody Activity Information 1 | [1] | |||||
|
Dissociation Constant (Kd)
|
1.05
|
nM
|
OVCAR-3 cells | CVCL_0465 | ||
|---|---|---|---|---|---|---|
| Antigen Expression | High LSR expression (LSR+++; 89382.9 LSR ABC/cell) | |||||
| Antibody Function | Confirm the effect of the drug conjugation with the anti LSR mAb and ADC on binding activity to cell line. | |||||
| Antibody Antigen Binding Assay | OVCAR3 cells were incubated with the unconjugated anti-LSR mAb (#16-6) or with the LSR-ADC. | |||||
Each Antibody-drug Conjugate Related to This Antibody
Full Information of The Activity Data of The ADC(s) Related to This Antibody
LSR-ADC [Investigative]
Discovered Using Patient-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 44.53% (Day 70) | High LSR expression (LSR+++; 89,382.9 LSR expression (ABC/cell)) | ||
| Method Description |
The model was Ovx6 PDX,which was generated by implanting human tumor tissues expressing LSR at high levels. When the mean tumor size of each cancer type reached approximately 110 mm3,PBS or LSR-ADC (1 mg/kg) were intravenously injected twice a week,for a total of four times.
|
||||
| In Vivo Model | Ovarian cancer PDX model (PDX: Ovx6) | ||||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 55.47% (Day 70) | High LSR expression (LSR+++; 89,382.9 LSR expression (ABC/cell)) | ||
| Method Description |
The model was Ovx6 PDX,which was generated by implanting human tumor tissues expressing LSR at high levels. When the mean tumor size of each cancer type reached approximately 110 mm3,PBS or LSR-ADC (3 mg/kg) were intravenously injected twice a week,for a total of four times.
|
||||
| In Vivo Model | Ovarian cancer PDX model (PDX: Ovx6) | ||||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 67.50% (Day 21) | High LSR expression (LSR+++; 89,382.9 LSR expression (ABC/cell)) | ||
| Method Description |
To assess the efficacy of LSR-ADC against omental/bowel metastasis,OVCAR3-Luc xenograft models were used. The OVCAR3-Luc xenograft models was established by implanting OVCAR3-Luc cells intraperitoneally,into the subscapular areas. Six or seven weeks after the inoculation,the treatment was initiated. PBS and 10 mg/kg of LSR-ADC were intravenously injected twice a week,for a total of four times.
Click to Show/Hide
|
||||
| In Vivo Model | Ovarian high-grade serous carcinoma PDX model (PDX: OVCAR3-LUC) | ||||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 97.24% (Day 70) | High LSR expression (LSR+++; 86,697.7 LSR expression (ABC/cell)) | ||
| Method Description |
The model was Ovx6 PDX,which was generated by implanting human tumor tissues expressing LSR at high levels. When the mean tumor size of each cancer type reached approximately 110 mm3,PBS or LSR-ADC (10 mg/kg) were intravenously injected twice a week,for a total of four times.
|
||||
| In Vivo Model | Ovarian cancer PDX model (PDX: Ovx6) | ||||
Discovered Using Cell Line-derived Xenograft Model
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 21.41% (Day 28) | High LSR expression (LSR+++) | ||
| Method Description |
The model was established by subcutaneously implanting OVCAR3 cells into CB17/SCID mice. When the mean tumor size of each cancer type reached approximately 110 mm3,PBS or LSR-ADC (1 mg/kg) were intravenously injected twice a week,for a total of four times.
|
||||
| In Vivo Model | Ovarian high-grade serous carcinoma CDX model | ||||
| In Vitro Model | Ovarian serous adenocarcinoma | OVCAR-3 cells | CVCL_0465 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 46.43% (Day 28) | High LSR expression (LSR+++) | ||
| Method Description |
The model was established by subcutaneously implanting OVCAR3 cells into CB17/SCID mice. When the mean tumor size of each cancer type reached approximately 110 mm3,PBS or LSR-ADC (3 mg/kg) were intravenously injected twice a week,for a total of four times.
|
||||
| In Vivo Model | Ovarian high-grade serous carcinoma CDX model | ||||
| In Vitro Model | Ovarian serous adenocarcinoma | OVCAR-3 cells | CVCL_0465 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Tumor Growth Inhibition value (TGI) | ≈ 99.01% (Day 28) | High LSR expression (LSR+++) | ||
| Method Description |
The model was established by subcutaneously implanting OVCAR3 cells into CB17/SCID mice. When the mean tumor size of each cancer type reached approximately 110 mm3,PBS or LSR-ADC (10 mg/kg) were intravenously injected twice a week,for a total of four times.
|
||||
| In Vivo Model | Ovarian high-grade serous carcinoma CDX model | ||||
| In Vitro Model | Ovarian serous adenocarcinoma | OVCAR-3 cells | CVCL_0465 | ||
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
449.00 pM
|
High LSR expression (LSR+++; 89,382.9 LSR expression (ABC/cell)) | ||
| Method Description |
Cytotoxicity assays were performed in the presence of the anti-LSR mAb (#16-6),the mouse IgG2a isotype control antibody,the LSR-ADC or the control-ADC. After 24 h,the cells were incubated with serial dilutions of the agents in triplicate wells for 144 h,at 37°C,in a humidified 5% CO2 atmosphere. Cell viability was determined with the CellTiter-Glo Luminescent Cell Viability Assay Kit.
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | OVCAR-3 cells | CVCL_0465 | ||
| Experiment 2 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
0.19 nM
|
High LSR expression (LSR+++; 86,697.7 LSR expression (ABC/cell)) | ||
| Method Description |
Cytotoxicity assays were performed in the presence of the anti-LSR mAb (#16-6),the mouse IgG2a isotype control antibody,the LSR-ADC or the control-ADC. After 24 h,the cells were incubated with serial dilutions of the agents in triplicate wells for 144 h,at 37°C,in a humidified 5% CO2 atmosphere. Cell viability was determined with the CellTiter-Glo Luminescent Cell Viability Assay Kit.
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian serous adenocarcinoma | OVCAR-3 Luc cells | CVCL_0465 | ||
| Experiment 3 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) |
1.74 nM
|
High LSR expression (LSR+++; 84,008.8 LSR expression (ABC/cell)) | ||
| Method Description |
Cytotoxicity assays were performed in the presence of the anti-LSR mAb (#16-6),the mouse IgG2a isotype control antibody,the LSR-ADC or the control-ADC. After 24 h,the cells were incubated with serial dilutions of the agents in triplicate wells for 144 h,at 37°C,in a humidified 5% CO2 atmosphere. Cell viability was determined with the CellTiter-Glo Luminescent Cell Viability Assay Kit.
Click to Show/Hide
|
||||
| In Vitro Model | Ovarian cancer ascites | NOVC-7C cells | Homo sapiens | ||
| Experiment 4 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal Inhibitory Concentration (IC50) | > 10.00 uM | Moderate LSR expression (LSR++; 2,631.9 LSR expression (ABC/cell)) | ||
| Method Description |
Cytotoxicity assays were performed in the presence of the anti-LSR mAb (#16-6),the mouse IgG2a isotype control antibody,the LSR-ADC or the control-ADC. After 24 h,the cells were incubated with serial dilutions of the agents in triplicate wells for 144 h,at 37°C,in a humidified 5% CO2 atmosphere. Cell viability was determined with the CellTiter-Glo Luminescent Cell Viability Assay Kit.
Click to Show/Hide
|
||||
| In Vitro Model | Ewing sarcoma | ES2 cells | CVCL_AX39 | ||
References
If you find any error in data or bug in web service, please kindly report it to Dr. Shen et al.